Pancreatic Cancer Non-resectable Clinical Trial
Official title:
Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study on the Efficacy and Safety of Huaier Granules Combined With Capecitabine Versus Capecitabine Alone in the Treatment of Unresectable Pancreatic Cancer
This is a prospective, multicenter, randomized, open, parallel controlled clinical study to evaluate the efficacy and safety of Huaier Granules combined with capecitabine in the treatment of unresectable pancreatic cancer.
This study is a prospective, multicenter, randomized, open label, parallel controlled clinical study. It is expected to include approximately 488 patients diagnosed with unresectable pancreatic adenocarcinoma by tissue or cellular pathology who visited the selected research center from April 2024 to March 2026. The treatment regimen will be capecitabine monotherapy orally. Among them, the Huaier group uses "capecitabine+Huaier granules", and is expected to include 244 cases; The control group received capecitabine and is expected to include 244 cases. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02128100 -
Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05047991 -
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT03590275 -
Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX
|
||
| Recruiting |
NCT05265663 -
Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients
|
N/A | |
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06160323 -
Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer
|
N/A | |
| Active, not recruiting |
NCT04156087 -
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03941093 -
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT03165591 -
Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05549414 -
Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System
|
N/A | |
| Recruiting |
NCT06388967 -
Pancreatic Cancer Detection Consortium
|
||
| Not yet recruiting |
NCT06375967 -
EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial)
|
N/A | |
| Withdrawn |
NCT04852367 -
PanDox: Targeted Doxorubicin in Pancreatic Tumours
|
Phase 1 | |
| Recruiting |
NCT03977233 -
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT03964064 -
I125 Seed Implantation vs Stereotactic Radiotherapy for Pancreatic Cancer
|
N/A | |
| Not yet recruiting |
NCT06361030 -
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05424159 -
Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
|
N/A | |
| Terminated |
NCT01887041 -
Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer
|
Phase 4 | |
| Active, not recruiting |
NCT03984214 -
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT05262452 -
Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer
|
N/A |